Evidence map›Paper›PMID 40752836›Full record

ArticleJournal of substance use and addiction treatment2025

Interest in contingency management and reducing stimulant use among syringe service program participants.

Tyler G Erath, Rosalie LaCroix, Erin O'Keefe, Michael DeSarno, Stephen T Higgins, Richard A Rawson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of substance use and addiction treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tyler G ErathVermont Center on Behavior and Health, Burlington, VT, USA; Department of Psychiatry, University of Vermont, Burlington, VT, USA. Electronic address: tyler.erath@uvm.edu.
Rosalie LaCroixHoward Center Safe Recovery, Burlington, VT, USA.
Erin O'KeefeHoward Center Safe Recovery, Burlington, VT, USA.
Michael DeSarnoVermont Center on Behavior and Health, Burlington, VT, USA; Medical Biostatistics, University of Vermont, Burlington, VT, USA.
Stephen T HigginsVermont Center on Behavior and Health, Burlington, VT, USA; Department of Psychiatry, University of Vermont, Burlington, VT, USA; Center on Rural Addictions, University of Vermont, Burlington, VT, USA.
Richard A RawsonVermont Center on Behavior and Health, Burlington, VT, USA; Department of Psychiatry, University of Vermont, Burlington, VT, USA; Center on Rural Addictions, University of Vermont, Burlington, VT, USA.

Funding

Vermont Center on Behavior and HealthP20GM103644 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HIGGINS, STEPHEN T · 2013 to 2022
$21.3M
Using Implementation Science to Advance Evidence-Based Treatment for Stimulant Use K01DA060309 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Tyler George Erath · 2025 to 2026
$405k
NIDA NIH HHS K01 DA060309NIGMS NIH HHS P20 GM103644
6 · The paper itself

Abstract

introductionExpanding access to effective treatment for stimulant use disorder (StimUD) is increasingly urgent as US fatal drug poisonings involving stimulants have rapidly increased. Limited information is available regarding interest in StimUD treatment among syringe service program (SSP) participants including interest in contingency management (CM).

methodsWe surveyed SSP participants in Burlington, Vermont regarding their interests in reducing and stopping stimulant use, participating in CM, and examined associations between sociodemographics, drug use, and health/treatment variables with interest in reducing and stopping stimulant use using multivariable logistic regression.

resultsAmong 139 participants, 64.6 % reported interest in reducing and 59.7 % in stopping stimulant use. Overall, 82.8 % of participants reported interest in CM to reduce or stop stimulant use. Interest in reducing use was greater (odds ratio[95 % CI]) among participants currently receiving substance use disorder (SUD) treatment (3.84[1.61-9.14], p < .01), without Hepatitis C viral (HCV) infection (2.61[1.14-5.98], p = .02), and being somewhat (19.29[2.25-165.65], p = .01) or very (19.65[2.34-164.84], p = .01) concerned about anxiety. Interest in stopping use was greater among participants currently receiving SUD treatment (4.98[1.97-12.62], p < .01), without HCV infection (2.87[1.22-6.74], p = .02), participants whose primary drug was opioids compared to both stimulants and opioids (28.13[2.95-267.93], p < .01), and participants whose primary drug was stimulants compared to both stimulants and opioids (12.81[1.45-113.43], p = .02).

conclusionsResults demonstrate interest in stimulant use treatment among this sample of SSP participants, with strong interest in CM. As community-based programs with high social acceptability for their non-judgmental services, SSPs are a novel setting to examine providing evidence-based CM for StimUD.

Indexed as

Behavior TherapyCentral Nervous System StimulantsNeedle-Exchange ProgramsSubstance Abuse, IntravenousSubstance-Related DisordersAdultFemaleHumansMaleMiddle AgedVermontYoung AdultCentral Nervous System StimulantsContingency managementHarm reductionStimulant use disorderSubstance use treatmentSyringe service program

Identifiers

PMID40752836
PMCPMC12358049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.